RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody

G. W. Philpott, S. W. Schwarz, C. J. Anderson, F. Dehdashti, J. M. Connett, K. R. Zinn, C. F. Meares, P. D. Cutler, M. J. Welch, B. A. Siegel

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Detection of tumor foci may be improved by combining the selective tumor- targeting properties of a monoclonal antibody with the superior sensitivity and contrast resolution of PET. Methods: An anti-colorectal carcinoma monoclonal antibody (MAb 1A3) was labeled with 64Cu, a positron-emitting radionuclide, by use of a bifunctional chelate (bromoacetamidobenzyl-TETA) and evaluated in 36 patients with suspected advanced primary or metastatic colorectal cancer. After radiopharmaceutical injection (5-20 mg protein, 10 mCi 64Cu), PET was performed once or twice, 4 to 36 hr later. All patients had CT scans and 18 patients were also studied with [18F]fluorodeoxyglucose (FDG) PET. Results: In 29 patients, one or more tumor sites (n = 56) were proven, in 5 patients the absence of active tumor was confirmed and in the remaining 2, tumor status is not yet confirmed. Of the 56 confirmed tumor sites, 40 were detected by MAb-PET as foci of increased activity (sensitivity 71%). The positive predictive value of MAb-PET was excellent, ranging from 89% (40/45) to 96% (43/45), depending on the ultimate classification of three image-positive, but as yet unconfirmed tumor sites. Also, MAb-PET detected 11 new occult tumor sites, including 9 small abdominopelvic foci less than 2.0 cm in diameter that were not detected by CT or MRI. There were no complications, but significantly elevated HAMA titers were found in 28% of the 29 patients tested I to 12 mo after injection. There was no apparent dose-related effect from 5 to 20 mg MAb 1A3. Conclusion: These Phase 1/11 results suggest that PET with radiolabeled MAbs (radioimmunoPET) may have important applications in clinical oncology, particularly for detecting smaller colorectal tumor foci in the abdomen or pelvis and for determining accurate dosimetry.

Original languageEnglish (US)
Pages (from-to)1818-1824
Number of pages7
JournalJournal of Nuclear Medicine
Volume36
Issue number10
StatePublished - 1995
Externally publishedYes

Fingerprint

Copper
Colorectal Neoplasms
Monoclonal Antibodies
Electrons
Neoplasms
Contrast Sensitivity
Injections
Medical Oncology
Radiopharmaceuticals
Fluorodeoxyglucose F18
Pelvis
Radioisotopes
Abdomen
Proteins

Keywords

  • colorectal cancer
  • copper-64-labeled MAb 1A3
  • radioimmunoPET

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Philpott, G. W., Schwarz, S. W., Anderson, C. J., Dehdashti, F., Connett, J. M., Zinn, K. R., ... Siegel, B. A. (1995). RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. Journal of Nuclear Medicine, 36(10), 1818-1824.

RadioimmunoPET : Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. / Philpott, G. W.; Schwarz, S. W.; Anderson, C. J.; Dehdashti, F.; Connett, J. M.; Zinn, K. R.; Meares, C. F.; Cutler, P. D.; Welch, M. J.; Siegel, B. A.

In: Journal of Nuclear Medicine, Vol. 36, No. 10, 1995, p. 1818-1824.

Research output: Contribution to journalArticle

Philpott, GW, Schwarz, SW, Anderson, CJ, Dehdashti, F, Connett, JM, Zinn, KR, Meares, CF, Cutler, PD, Welch, MJ & Siegel, BA 1995, 'RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody', Journal of Nuclear Medicine, vol. 36, no. 10, pp. 1818-1824.
Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, Zinn KR et al. RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. Journal of Nuclear Medicine. 1995;36(10):1818-1824.
Philpott, G. W. ; Schwarz, S. W. ; Anderson, C. J. ; Dehdashti, F. ; Connett, J. M. ; Zinn, K. R. ; Meares, C. F. ; Cutler, P. D. ; Welch, M. J. ; Siegel, B. A. / RadioimmunoPET : Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. In: Journal of Nuclear Medicine. 1995 ; Vol. 36, No. 10. pp. 1818-1824.
@article{18149889bdd24c40bd99988da6c23368,
title = "RadioimmunoPET: Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody",
abstract = "Detection of tumor foci may be improved by combining the selective tumor- targeting properties of a monoclonal antibody with the superior sensitivity and contrast resolution of PET. Methods: An anti-colorectal carcinoma monoclonal antibody (MAb 1A3) was labeled with 64Cu, a positron-emitting radionuclide, by use of a bifunctional chelate (bromoacetamidobenzyl-TETA) and evaluated in 36 patients with suspected advanced primary or metastatic colorectal cancer. After radiopharmaceutical injection (5-20 mg protein, 10 mCi 64Cu), PET was performed once or twice, 4 to 36 hr later. All patients had CT scans and 18 patients were also studied with [18F]fluorodeoxyglucose (FDG) PET. Results: In 29 patients, one or more tumor sites (n = 56) were proven, in 5 patients the absence of active tumor was confirmed and in the remaining 2, tumor status is not yet confirmed. Of the 56 confirmed tumor sites, 40 were detected by MAb-PET as foci of increased activity (sensitivity 71{\%}). The positive predictive value of MAb-PET was excellent, ranging from 89{\%} (40/45) to 96{\%} (43/45), depending on the ultimate classification of three image-positive, but as yet unconfirmed tumor sites. Also, MAb-PET detected 11 new occult tumor sites, including 9 small abdominopelvic foci less than 2.0 cm in diameter that were not detected by CT or MRI. There were no complications, but significantly elevated HAMA titers were found in 28{\%} of the 29 patients tested I to 12 mo after injection. There was no apparent dose-related effect from 5 to 20 mg MAb 1A3. Conclusion: These Phase 1/11 results suggest that PET with radiolabeled MAbs (radioimmunoPET) may have important applications in clinical oncology, particularly for detecting smaller colorectal tumor foci in the abdomen or pelvis and for determining accurate dosimetry.",
keywords = "colorectal cancer, copper-64-labeled MAb 1A3, radioimmunoPET",
author = "Philpott, {G. W.} and Schwarz, {S. W.} and Anderson, {C. J.} and F. Dehdashti and Connett, {J. M.} and Zinn, {K. R.} and Meares, {C. F.} and Cutler, {P. D.} and Welch, {M. J.} and Siegel, {B. A.}",
year = "1995",
language = "English (US)",
volume = "36",
pages = "1818--1824",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - RadioimmunoPET

T2 - Detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody

AU - Philpott, G. W.

AU - Schwarz, S. W.

AU - Anderson, C. J.

AU - Dehdashti, F.

AU - Connett, J. M.

AU - Zinn, K. R.

AU - Meares, C. F.

AU - Cutler, P. D.

AU - Welch, M. J.

AU - Siegel, B. A.

PY - 1995

Y1 - 1995

N2 - Detection of tumor foci may be improved by combining the selective tumor- targeting properties of a monoclonal antibody with the superior sensitivity and contrast resolution of PET. Methods: An anti-colorectal carcinoma monoclonal antibody (MAb 1A3) was labeled with 64Cu, a positron-emitting radionuclide, by use of a bifunctional chelate (bromoacetamidobenzyl-TETA) and evaluated in 36 patients with suspected advanced primary or metastatic colorectal cancer. After radiopharmaceutical injection (5-20 mg protein, 10 mCi 64Cu), PET was performed once or twice, 4 to 36 hr later. All patients had CT scans and 18 patients were also studied with [18F]fluorodeoxyglucose (FDG) PET. Results: In 29 patients, one or more tumor sites (n = 56) were proven, in 5 patients the absence of active tumor was confirmed and in the remaining 2, tumor status is not yet confirmed. Of the 56 confirmed tumor sites, 40 were detected by MAb-PET as foci of increased activity (sensitivity 71%). The positive predictive value of MAb-PET was excellent, ranging from 89% (40/45) to 96% (43/45), depending on the ultimate classification of three image-positive, but as yet unconfirmed tumor sites. Also, MAb-PET detected 11 new occult tumor sites, including 9 small abdominopelvic foci less than 2.0 cm in diameter that were not detected by CT or MRI. There were no complications, but significantly elevated HAMA titers were found in 28% of the 29 patients tested I to 12 mo after injection. There was no apparent dose-related effect from 5 to 20 mg MAb 1A3. Conclusion: These Phase 1/11 results suggest that PET with radiolabeled MAbs (radioimmunoPET) may have important applications in clinical oncology, particularly for detecting smaller colorectal tumor foci in the abdomen or pelvis and for determining accurate dosimetry.

AB - Detection of tumor foci may be improved by combining the selective tumor- targeting properties of a monoclonal antibody with the superior sensitivity and contrast resolution of PET. Methods: An anti-colorectal carcinoma monoclonal antibody (MAb 1A3) was labeled with 64Cu, a positron-emitting radionuclide, by use of a bifunctional chelate (bromoacetamidobenzyl-TETA) and evaluated in 36 patients with suspected advanced primary or metastatic colorectal cancer. After radiopharmaceutical injection (5-20 mg protein, 10 mCi 64Cu), PET was performed once or twice, 4 to 36 hr later. All patients had CT scans and 18 patients were also studied with [18F]fluorodeoxyglucose (FDG) PET. Results: In 29 patients, one or more tumor sites (n = 56) were proven, in 5 patients the absence of active tumor was confirmed and in the remaining 2, tumor status is not yet confirmed. Of the 56 confirmed tumor sites, 40 were detected by MAb-PET as foci of increased activity (sensitivity 71%). The positive predictive value of MAb-PET was excellent, ranging from 89% (40/45) to 96% (43/45), depending on the ultimate classification of three image-positive, but as yet unconfirmed tumor sites. Also, MAb-PET detected 11 new occult tumor sites, including 9 small abdominopelvic foci less than 2.0 cm in diameter that were not detected by CT or MRI. There were no complications, but significantly elevated HAMA titers were found in 28% of the 29 patients tested I to 12 mo after injection. There was no apparent dose-related effect from 5 to 20 mg MAb 1A3. Conclusion: These Phase 1/11 results suggest that PET with radiolabeled MAbs (radioimmunoPET) may have important applications in clinical oncology, particularly for detecting smaller colorectal tumor foci in the abdomen or pelvis and for determining accurate dosimetry.

KW - colorectal cancer

KW - copper-64-labeled MAb 1A3

KW - radioimmunoPET

UR - http://www.scopus.com/inward/record.url?scp=0028786707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028786707&partnerID=8YFLogxK

M3 - Article

C2 - 7562049

AN - SCOPUS:0028786707

VL - 36

SP - 1818

EP - 1824

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -